BioRestorative Therapies (BRTX) Cash from Financing Activities (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Cash from Financing Activities came in at $923243.0 in Q4 2025, up 830.9% YoY from $99177.5 in Q4 2024, and up 1972.4% on a QoQ basis from -$49308.0 in Q3 2025.
BioRestorative Therapies (BRTX) Cash from Financing Activities (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Cash from Financing Activities data on file, last reported at $923243.0 in Q4 2025.
- Quarterly Cash from Financing Activities rose 830.9% year-over-year to $923243.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 61.31% YoY) and the FY2025 annual result came in at $2.9 million, down 61.31% from the prior year.
- Cash from Financing Activities advanced to $923243.0 in Q4 2025, from -$49308.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $21.1 million in Q4 2021 to a low of -$126316.0 in Q4 2024.
- A 4-year average of $3.0 million and a median of $888138.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 252.05% — and 2025, when it soared 7015.35%.
- Tracing BRTX's Cash from Financing Activities over 4 years: stood at $21.1 million in 2021, then sank by 99.61% to $83073.0 in 2023, then tumbled by 252.05% to -$126316.0 in 2024, then jumped by 830.9% to $923243.0 in 2025.
- The last three Cash from Financing Activities figures came in at $923243.0 (Q4 2025), -$49308.0 (Q3 2025), and $888138.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 923,243.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 923,243.00 |
| Dec 31, 2025 | 923,243.00 |
| Sep 30, 2025 | -49,308.00 |
| Sep 30, 2025 | -49,308.00 |
| Jun 30, 2025 | 888,138.00 |
| Jun 30, 2025 | 888,138.00 |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | -126,316.00 |
| Dec 31, 2024 | -126,316.00 |
| Jun 30, 2024 | -12,843.00 |
| Jun 30, 2024 | -12,843.00 |
| Mar 31, 2024 | 7.52 Mn |
| Mar 31, 2024 | 7.52 Mn |
| Dec 31, 2023 | 83,073.00 |
| Dec 31, 2023 | 83,073.00 |
| Sep 30, 2023 | 1.85 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Dec 31, 2021 | 21.07 Mn |
| Dec 31, 2021 | 21.07 Mn |